Nigel McCracken
Chief Tech/Sci/R&D Officer bei BERGENBIO ASA
Profil
Nigel McCracken is currently the Chief Scientific Officer at BerGenBio ASA and the Chief Operating Officer at Virax Biolabs Group Ltd.
He previously worked as the Executive Director & VP-Translational Medicine at Debiopharm International SA from 2014 to 2019.
He also held a position as COO and Senior VP-Discovery & Early Development at NuCana Plc.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and his graduate degree from King's College London.
Aktive Positionen von Nigel McCracken
| Unternehmen | Position | Beginn |
|---|---|---|
| BERGENBIO ASA | Chief Tech/Sci/R&D Officer | 01.01.2021 |
| VIRAX BIOLABS GROUP LIMITED | Chief Operating Officer | 01.09.2023 |
Ehemalige bekannte Positionen von Nigel McCracken
| Unternehmen | Position | Ende |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Director/Board Member | 01.04.2019 |
| NUCANA PLC | Chief Operating Officer | - |
Ausbildung von Nigel McCracken
| University of Strathclyde | Undergraduate Degree |
| King's College London | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BERGENBIO ASA | Health Technology |
| NUCANA PLC | Health Technology |
| VIRAX BIOLABS GROUP LIMITED | Finance |
| Private Unternehmen | 1 |
|---|---|
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
